Prevention and Medicare Costs
- 15 October 1998
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 339 (16) , 1158-1160
- https://doi.org/10.1056/nejm199810153391612
Abstract
Once viewed as an inevitable consequence of aging, cardiovascular disease is now known to be related to modifiable risk factors, especially smoking, elevated blood pressure, and elevated cholesterol. Numerous preventive interventions have been developed in recent decades to combat these risk factors. The issue now is how best to allocate resources among these interventions in order to prevent disease.Antihypertensive drugs, for example, though effective, vary widely in their cost effectiveness. Propranolol costs $20,000 to save a year of life (life-year) for adults 35 to 64 years of age, and captopril costs $130,0001 (the medical component of the Consumer Price . . .Keywords
This publication has 13 references indexed in Scilit:
- Benefit of a Favorable Cardiovascular Risk-Factor Profile in Middle Age with Respect to Medicare CostsNew England Journal of Medicine, 1998
- Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and ResearchJAMA, 1997
- Folic acid fortification of the food supply. Potential benefits and risks for the elderly populationPublished by American Medical Association (AMA) ,1996
- Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Recommendations of the Panel on Cost-effectiveness in Health and MedicinePublished by American Medical Association (AMA) ,1996
- The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakesPublished by American Medical Association (AMA) ,1995
- Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart diseasePublished by American Medical Association (AMA) ,1991
- Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertensionPublished by American Medical Association (AMA) ,1990
- Foundations of Cost-Effectiveness Analysis for Health and Medical PracticesNew England Journal of Medicine, 1977